New hope for Hard-to-Treat ovarian cancer: drug combo trial launches

NCT ID NCT07637851

Not yet recruiting Disease control Sponsor: ARCAGY/ GINECO GROUP Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tumors. Participants will receive three cycles of the combination, then maintenance therapy for up to 15 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube carcinoma fallopian tube serous adenocarcinoma ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Centre Eugène Marquis

Rennes, 35042, France
Centre François Baclesse

Caen, 14076, France
Centre Georges François Leclerc

Dijon, 21079, France
Centre Léon Bérard

Lyon, 69373, France
Gustave Roussy

Villejuif, 94805, France
HCL - Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Hôpital de Hautepierre

Strasbourg, 67098, France
ICM Val d'Aurelle

Montpellier, 34298, France
ICO - Centre René Gauducheau

Saint-Herblain, 44805, France
Institut Bergonié

Bordeaux, 33076, France
Institut Paoli Calmettes

Marseille, 13273, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.